

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

**VOLUNTARY ANNOUNCEMENT
LICENSING AND SUPPLY AGREEMENT REACHED BETWEEN
XUANZHU BIOPHARM
AND BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that on 9 April, 2026, Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharm**”, stock code: 02575.HK), a non wholly-owned subsidiary of the Group, entered into a licensing and supply agreement (the “**Agreement**”) with Boston Oncology CGT Holding Co. Limited (“**Boston Oncology**”) in respect of Bireociclib (trade name: Xuan Yue Ning) and Dirozalkib (trade name: Xuan Fei Ning). Bireociclib is a CDK2/4/6 inhibitor independently developed by Xuanzhu Biopharm for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (“**HR+/HER2-**”) advanced breast cancer; Dirozalkib is a next-generation anaplastic lymphoma kinase (“**ALK**”) inhibitor independently developed by Xuanzhu Biopharm for the treatment of ALK-positive advanced non-small cell lung cancer.

Under the licensing and supply agreement, Xuanzhu Biopharm will grant Boston Oncology an exclusive license to develop, register and commercialize Bireociclib and Dirozalkib within the licensed territory (21 countries and regions in the Middle East and North Africa (MENA) region). Xuanzhu Biopharm will receive an upfront payment and potential regulatory and commercial milestone payments which may cumulatively exceed US\$100 million, as well as royalties at a fixed percentage of total sales within the licensed territory. Xuanzhu Biopharm will supply products to Boston Oncology at product supply prices agreed upon by both parties, so as to meet the commercial development activities for both drugs within the licensed territory.

The execution of the Agreement is an important strategic initiative for Xuanzhu Biopharm in its global market expansion. Leveraging Boston Oncology's established advantages in pharmaceutical registration, commercial promotion and distribution systems within the MENA region, Xuanzhu Biopharm can rapidly advance the market entry and commercialization of Bireociclib and Dirozalkib in the licensed territory, thereby further enhancing the global market coverage and brand influence of Xuanzhu Biopharm's innovative drugs. This cooperation is in line with the Group's core strategy of "innovation driven, global development", the fulfillment of this Agreement will bring sustained milestone and royalty income to Xuanzhu Biopharm and the Group, optimize its revenue structure, and is in the overall interests of Xuanzhu Biopharm, the Group and all shareholders.

ABOUT BIREOCICLIB

Bireociclib Tablets (trade name: Xuan Yue Ning), as the first CDK2/4/6 inhibitor approved in China, possesses a unique multi-target synergistic mechanism of action, offering advantages including potent inhibition of tumor cell proliferation and significant reduction of the hematological toxicity commonly associated with traditional CDK4/6 inhibitors. In May 2025, Bireociclib Tablets were approved by the National Medical Products Administration (NMPA) for use in combination with fulvestrant for the treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer who have experienced disease progression following prior endocrine therapy; and as monotherapy for the treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer who have experienced disease progression following two or more prior endocrine therapies and one chemotherapy regimen during the metastatic stage, making it the first and only CDK2/4/6 inhibitor approved with a monotherapy indication in China. In March 2026, Bireociclib Tablets received approval for an additional indication, for use in combination with aromatase inhibitors (AIs) for the initial endocrine treatment of patients with HR+/HER2- locally advanced or metastatic breast cancer. In December 2025, both indications for Bireociclib Tablets, in combination with fulvestrant and as monotherapy, were included in the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2025), effective from January 1, 2026.

ABOUT DIROZALKIB

Dirozalkib Tablets (trade name: Xuan Fei Ning) are a next-generation oral ALK inhibitor independently developed by Xuanzhu Biopharm, specifically designed for the treatment of ALK rearranged advanced non-small cell lung cancer (NSCLC). Dirozalkib features a novel molecular structure with stronger affinity for the ATP-binding site within the ALK kinase domain, demonstrating potent inhibitory activity against common resistance mutations associated with first-generation and most second-generation ALK inhibitors, including G1202R and I1171N, and is capable of achieving significant intracranial anti-tumor efficacy through efficient penetration of the blood-brain barrier. In August 2025, Dirozalkib was approved by the NMPA for the treatment of patients with ALK-positive locally advanced or metastatic NSCLC who have not been previously treated with an anaplastic lymphoma kinase (ALK) inhibitor.

ABOUT BOSTON ONCOLOGY

Boston Oncology is headquartered in Cambridge, Massachusetts, United States, with a regional operations center established in Riyadh, Saudi Arabia, and focuses on the localized development, production and manufacturing of oncology drugs and biosimilars. Through pharmaceutical licensing, technology transfer and regionalized production models, it introduces international quality and manufacturing standards to the Middle East market, continuously advancing the local supply of drugs in key therapeutic areas and supporting the coordinated development of the regional pharmaceutical industry. As far as Xuanzhu Biopharm's directors are aware after making all reasonable enquiries, Boston Oncology and its ultimate beneficial owners are independent third parties independent of Xuanzhu Biopharm and its connected persons (as defined in the Listing Rules).

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm was listed on the Main Board of The Stock Exchange of Hong Kong Limited in October 2025 (stock code: 02575.HK). It is an innovative pharmaceutical company rooted in China with a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development (“R&D”), production and commercialization of class 1 innovative drugs with core proprietary intellectual property rights. The company has a first-class R&D team that all core personnel have years of experience in new drug R&D. The company has two R&D platforms: small molecule chemistry and large molecule biopharmaceuticals. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the company is committed to developing into a first class innovative pharmaceutical company with independent R&D, production, and sales capabilities.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 9 April 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.